P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Up 32.8% in December

P3 Health Partners Inc. (NASDAQ:PIII) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 24,688 shares, a growth of 32.8% from the December 15th total of 18,589 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 16,172 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily volume of 16,172 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.4% of the shares of the company are short sold.

P3 Health Partners Price Performance

Shares of PIII traded down $0.10 during mid-day trading on Friday, reaching $3.20. 34,064 shares of the stock traded hands, compared to its average volume of 13,804. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 2.29. P3 Health Partners has a 1 year low of $2.87 and a 1 year high of $12.44. The company has a market cap of $23.06 million, a price-to-earnings ratio of -0.08 and a beta of 0.90. The firm has a fifty day moving average price of $4.77 and a 200 day moving average price of $6.81.

P3 Health Partners (NASDAQ:PIII) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($9.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.70) by ($0.97). P3 Health Partners had a negative net margin of 9.07% and a negative return on equity of 302.33%. The business had revenue of $345.25 million for the quarter, compared to the consensus estimate of $346.64 million. As a group, equities research analysts predict that P3 Health Partners will post -0.67 earnings per share for the current year.

Wall Street Analyst Weigh In

PIII has been the topic of several research reports. BTIG Research reissued a “neutral” rating on shares of P3 Health Partners in a research report on Friday, December 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of P3 Health Partners in a report on Wednesday, October 8th. Finally, Lake Street Capital cut their price target on P3 Health Partners from $20.00 to $12.50 and set a “buy” rating for the company in a report on Monday, November 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $12.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in P3 Health Partners stock. Trinity Financial Advisors LLC raised its stake in shares of P3 Health Partners Inc. (NASDAQ:PIII) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,678 shares of the company’s stock after purchasing an additional 1,178 shares during the quarter. Trinity Financial Advisors LLC owned 0.37% of P3 Health Partners worth $239,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 7.75% of the company’s stock.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.